Vivaldi Biosciences
Signal active
Organization
Contact Information
Overview
Vivaldi Biosciences Inc. develops influenza vaccines and therapeutics for seasonal and pandemic influenza through a small molecule program targeting the NS1 protein of influenza. The company was founded in 2006 and is based in San Francisco, California.
About
Industries
Biotechnology, Life Science, Medical Device
Founded
2006
Employees
11-50
Headquarters locations
New York, New York, United States, North America
Social
N/A
Profile Resume
Vivaldi Biosciences headquartered in New York, New York, United States, North America, operates in the Biotechnology, Life Science, Medical Device sector. The company focuses on Biotechnology and has secured $971.1M in funding across 36 round(s). With a team of 11-50 employees, Vivaldi Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Vivaldi Biosciences, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
1
Lead Investors
0
Total Funding Amount
$27.0M
Details
2
Vivaldi Biosciences has raised a total of $27.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2009 | Early Stage Venture | 23.0M | ||
| 2007 | Early Stage Venture | 2.0M |
Investors
Vivaldi Biosciences is funded by 5 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Bay City Capital | - | FUNDING ROUND - Bay City Capital | 23.0M |
| Peter Johann | - | FUNDING ROUND - Peter Johann | 23.0M |
| Vivaldi Biosciences | - | FUNDING ROUND - Vivaldi Biosciences | 23.0M |
| NGN Capital | - | FUNDING ROUND - NGN Capital | 23.0M |
Recent Activity
There is no recent news or activity for this profile.